PARATEK PHARMACEUTICALS, INC.
Presenter SpeechEvan Loh (Executives)Good morning. My name is Evan Loh, CEO of Paratek Pharmac...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia (CABP), and acute skin and skin structure infections (ABSSSI) caused by susceptible pathogens. Its other commercial product SEYSARA (sarecycline), is a once-daily oral therapy for the treatment of moderate to severe acne vulgaris. The Sarecycline is a narrow spectrum tetracycline designed specifically for dermatological use. It markets omadacycline in the United States as an empiric monotherapy in the indications of ABSSSI and CABP for patients that have both a known or suspected resistant pathogen and at least one significant comorbidity.
Sector
Pharmaceuticals
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +32.07% | 694B | |
| +29.39% | 593B | |
| -1.75% | 371B | |
| +19.95% | 331B | |
| +6.87% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +7.93% | 169B |
